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Fig 1. National Inpatient Sample (NIS) carotid artery stenting (CAS;
moving average). CMS, Centers for Medicare and Medicaid Services;
CREST, Carotid Revascularization Endarterectomy vs. Stent Trial.
Fig 2. Vascular Study Group of New England (VSGNE): carotid artery
stenting (CAS; moving average). CMS, Centers for Medicare and Medicaid
Services; CREST, Carotid Revascularization Endarterectomy vs. Stent Trial.
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Objectives: Vascular access thrombosis (VAT) is a severe complica-
tion that needs a timely treatment. The annual incidence of VAT and the
timeliness of its treatment are not currently known.
Methods: A comprehensive survey of all the nephrologists stafﬁng
all hemodialysis centers in France was performed during March and April
2013. The number of patients, percentage of permanent or temporary
catheter use, incidence of VAT, specialty of the referral physician con-
sulted to treat VAT, and mean time to treatment were recorded for
each center. Data were compared between rural and urban zones of
each center.
Results: A total of 266 of 269 centers (99%) participated, with 114
private centers, 118 hospitals, and 37 academic hospitals treating 32,461 he-
modialysis patients. A total of 27,798 patients (85%) used an arteriovenous
(AV) ﬁstula or graft, and 4663 (15%) required a permanent catheter. In 104
centers treating 11,088 patients with AV ﬁstula or grafts, there were 905
documented episodes of VAT (8.2%) in 1 year; in the other 162 centers
that supplied a range, the mean incidence of VAT was 8.5%. Immediately
after diagnosis, 8% of the centers routinely placed a temporary catheter,
and 26% never placed any catheter. Fifty-three percent of centers refer
VAT to a vascular surgeon (VS) and 32% to an interventional radiologist
(IR), with only 2% to urology and 13% variable referral depending on
case complexity. There was a difference in referral patterns between rural
(VS, 75%; IR, 25%) and urban centers (VS, 49%; IR, 51%). Time to treat-
ment was <24 hours in 58% of the centers and <48 hours in 91% of the
centers; treatment >48 hours (9%) occurred predominantly in rural zones
(P ¼ .04). The specialty of the treating physician did not inﬂuence time
to treatment (P > .05).
Conclusion: The annual incidence of VAT is 8%, and 91% of cases in
France are treated #48 hours, consistent with European treatment guide-
lines. There is a disparity between rural and urban centers regarding the spe-
cialty of the treating physician. Increasing access to VSs may be an
alternative to regionalization of specialty care.
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Objectives: Since approval of carotid artery stenting (CAS), there
have been two seminal publications about CAS reimbursement (Centers
for Medicare and Medicaid Services, 2008) and results (Carotid Revascular-
ization Endarterectomy vs. Stent Trial [CREST], 2010). We explored
trends in CAS utilization after these publications nationally (National Inpa-
tient Sample [NIS]) among different specialties performing CAS and
regionally (Vascular Study Group of New England [VSGNE]) among
mostly vascular surgeons.
Methods: The most recent data sets of NIS and VSGNE were
queried for patients undergoing CAS using appropriate International
Classiﬁcation of Diseases-9th Edition codes. Utilization proportions of
CAS were calculated quarterly from 2005 to 2011 for NIS and from
2005 to 2013 for VSGNE. Three time intervals were selected Q1/
2005 to Q2/2008 (P1), Q2/2008 to Q3/2010 (P2), and after Q3/
2010 (P3) related to CMS guidelines and the CREST publication. Logis-
tic regression with terms modeling change in the odds ratio (OR) for the
second and third time intervals was used to estimate different trends in
CAS utilization for overall samples and for symptomatic and asymptom-
atic cases.>Eastern Vascular Society
yNew England Society for Vascular SurgeryResults: In the NIS sample, 95% of CAS was performed in asymptom-
atic patients vs 67% in the VSGNE data set. Overall CAS utilization was
higher nationally than regionally (12.51% in NIS vs 5.64% in VSGNE).
CAS was used more frequently for symptomatic patients in VSGNE
(6.36% vs 5.31%; P ¼ .032) and in NIS (19.12% vs 12.17%, P < .001) sam-
ples. Nationally, there were signiﬁcant increases in frequency of CAS in P1
(P < .001) and P3 (P ¼ .027), with a plateau during P2 (P ¼ .599). In
VSGNE, we observed an overall signiﬁcant decrease in CAS during P1
(P ¼ .004) and then signiﬁcant increases in CAS in P2 (P ¼ .036) and in
P3 (P ¼ .005). Fig 1 and Fig 2 summarize trends for the overall, symptom-
atic, and asymptomatic groups.
Conclusions: Overall use of CAS has increased since 2005 but was
not uniformly affected by CMS guidelines or the CREST publication.
The CAS use within VSGNE followed a more predictable pattern.
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Objectives: Vascular reconstruction can facilitate pancreas tumor
resection, but optimal methods of reconstruction are not well studied. We
analyzed our results for portal vein reconstruction (PVR) for pancreatic
resection and determinants of postoperative patency.>Eastern Vascular Society
